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Type I interferons (IFNs) play both beneficial and
harmful roles in antiviral responses. Precise regula-
tion of host type I IFNs is thus needed to prevent im-
mune dysregulation. Here, we find that the DNA
demethylase TET3 is a negative regulator of IFN-b
in response to poly(I:C) stimulation or viral infection.
Deletion of TET3 enhances antiviral responses, with
elevated expression of IFN-b and IFN-stimulated
genes. The catalytic domain of TET3 was critical for
the suppression of IFN-b production, but TET3 enzy-
matic activity was dispensable. Instead, the catalytic
domain of TET3 interacts with HDAC1 and SIN3A,
thus enhancing their binding to the Ifnb1 promoter.
Our study demonstrates that TET3 negatively regu-
lates type I IFN production independent of DNA de-
methylation. This not only sheds light on TET3 as a
signaling protein in immune cells for gene regulation
but also will help to develop strategies to prevent
type I IFN-related disease.INTRODUCTION
Type I interferons (IFNs) include IFN-a and IFN-b. Accumulating
evidence suggests that type I IFNs play multifaceted roles in dis-
eases (Trinchieri, 2010). Initially, type I IFNs were discovered as
critical antiviral cytokines, and recent reports suggest that the
blockade of type I IFN signaling in virus-induced chronic infec-
tion could decrease immune suppression and accelerate the
clearance of persistent infections (Teijaro et al., 2013; Wilson
et al., 2013). During bacterial infections, type I IFNs could protect
the host through the production of proinflammatory cytokines,
but type I IFNs are also suggested to be hijacked by Listeria to
induce exaggerated apoptosis (Carrero et al., 2004). In addition
to infectious diseases, type I IFNs might also act as double-
edged swords in autoimmune diseases. Excessive interferon is1096 Cell Reports 16, 1096–1105, July 26, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://recognized as a prominent aspect in patients with systemic
lupus erythematosus (SLE) (Ro¨nnblom et al., 2009), and IFN-b
is used as a drug to treat multiple sclerosis (Comi, 2009; Nose-
worthy et al., 2000). Therefore, precise regulation of type I IFN
production is critical in order to maintain host homeostasis.
The production of type I IFN could be modulated in various
ways. Post-translational modifications, including phosphoryla-
tion and ubiquitination, are critical for modulating signal trans-
duction during type I IFN production (Richards and Macdonald,
2011). Notably, epigenetic modifiers are among the key players
at the transcriptional level for type I IFN regulation, altering chro-
matin accessibility for transcription factors (Ford and Thanos,
2010). Histone modifications such as acetylation and methyl-
ation could be efficiently switched on and off, which makes
histones ideal for efficiently regulating gene transcription (A´l-
varez-Errico et al., 2015). As for DNA modifications, methylated
cytosine in the promoter region has been suggested for tran-
scriptional silencing (Sch€ubeler, 2015), and TET family members
have been recently discovered as new DNA demethylases for
gene activation (Hu et al., 2015; Tahiliani et al., 2009).
The TET family of proteins, including TET1, TET2 and TET3,
can catalyze the oxidation of the methyl group on cytosine (He
et al., 2011). TET family members have been shown to partici-
pate in numerous development processes (Branco et al.,
2012), including hematopoiesis. TET2mutations are contributors
to hematologic neoplasms, and mouse studies have suggested
that mutated TET2 results in aberrant common myeloid progen-
itor (CMP) differentiation (Figueroa et al., 2010; Moran-Crusio
et al., 2011; Quivoron et al., 2011). In addition, TET1 has been
suggested as a tumor suppressor in non-Hodgkin B cell lym-
phoma (Cimmino et al., 2015). As noted previously, emerging
evidence has demonstrated that the TET family also has an
essential role in immune cells. In T cells, TET2 is able to regulate
FoxP3 expression and affects the differentiation and homeosta-
sis of CD4+FoxP3+ regulatory T cells (Yang et al., 2015). In
myeloid cells, a recent discovery shows that TET2 is involved
in interleukin 6 (IL-6) production (Zhang et al., 2015). TET3 is
also expressed in immune cells, but its role in the production
of type I IFN by immune cells is undefined..
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. TET3 Suppresses IFN-b Production
via the TLR3 Pathway
(A) Relative mRNA expression of Tet1, Tet2, and
Tet3 in BMDMs.
(B) Paired analysis of the relative mRNA expression
of Tet1 (left), Tet2 (middle), and Tet3 (right) in PEMs
that were unstimulated (Mock) or stimulated with
poly(I:C).
(C) Relative IFN-b luciferase activity in HEK293T
cells transfected with TET3 or the empty control
vector, with or without the constitutively active form
of IRF3. Arrow indicates TET3 protein levels (right).
(D) Relative IFN-b luciferase activity in HEK293T
cells transfected with vector plasmid (1,000 ng) or
various concentrations of TET3 plasmids (10 ng,
100 ng, or 1,000 ng), along with the constitutively
active form of IRF3.
(E) The relative mRNA expression of Ifnb1 in WT and
Tet3-het BMDMs stimulated with poly(I:C) for the
indicated time. Relative mRNA expression of Tet3 in
WT and Tet3-het BMDMs (right).
(F) IFN-b concentrations in the supernatants of WT
and Tet3-het BMDMs that were unstimulated or
stimulated with poly(I:C) for 16 hr.
(G) The relative mRNA expression of Ifnb1 in the
control or Tet3-knockdown PEMs stimulated with
poly(I:C). Right panel shows the knockdown effi-
ciency.
(H) Relative mRNA expression of Ifnb1 in WT and
Tet3-het BMDMs after LPS stimulation.
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.Here, we provide evidence that TET3 inhibited the production
of type I IFNs, especially IFN-b, and deletion of TET3 in macro-
phages enhanced antiviral responses. Suppression of IFN-b pro-
duction by TET3 was mediated by the HDAC1-SIN3A module,
which was independent of the DNA demethylation activity of
TET3.
RESULTS
TET3 Suppresses IFN-b Production via the TLR3
Pathway
To investigate the role of TET family members in IFN-b produc-
tion, we first analyzed the mRNA expression levels of Tet1,
Tet2, and Tet3 in primary murine bone-marrow-derived macro-
phages (BMDMs). TET3 showed the highest expression level
among TET family members, while TET1 was barely expressed
in macrophages (Figure 1A). The Toll-like receptor 3 (TLR3)
pathway is a well-characterized pathway producing type I IFNs
and is critical in host defense against various viruses (HoebeCellet al., 2003; Li et al., 2005; Zhang et al.,
2007). We stimulated murine BMDMs
with poly(I:C) to activate the TLR3
pathway. mRNA levels of Tet3, rather
than Tet1 and Tet2, were significantly
decreased compared to those of the unsti-
mulated BMDMs (Figure 1B). We thereforeasked whether TET3 might regulate TLR3-mediated type I IFN
production. When compared to poly(I:C)-treated wild-type (WT)
macrophages, mRNA levels of Ifnb1, which encodes IFN-b,
were not significantly changed in Tet1 knockout (KO) macro-
phages (Figure S1A). Because we did not have Tet2 KO mice
and Tet3 KO mice are embryonic lethal, we transfected
HEK293T cells with plasmids expressing TET2 or TET3 together
with the IFN-b luciferase reporter to evaluate IFN-b levels. The
constitutively active form of IRF3 was also transfected into these
HEK293T cells to stimulate IFN-b production, as previously
described (Li et al., 2015b). Compared to the vector control cells,
overexpression of TET2 showed comparable IFN-b induction
(Figure S1B); in contrast, overexpression of TET3 significantly
reduced IFN-b luciferase readings (Figure 1C). When TET3 over-
expression levels were gradually increased, inhibition of IFN-b
induction was dose dependent (Figure 1D). Because TET3 defi-
ciency results in embryonic lethality in mice, we next used pri-
mary BMDMs from WT and Tet3-heterozygous (Tet3-het) mice
(Figure 1E; the mRNA levels of Tet3 are shown in the right panel).Reports 16, 1096–1105, July 26, 2016 1097
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Figure 2. TET3 Suppresses IFN-b Production
via the RIG-I/MDA-5 Pathway
(A) Relative mRNA expression of Ifnb1 in WT and
Tet3-het BMDMs after poly(I:C) transfection.
(B) Relative mRNA expression of Ifnb1 in control or
Tet3-knockdown PEMs transfected with poly(I:C).
Right panel indicates the knockdown efficiency.
(C) MEFs targeted with control sgRNA (WT) or Tet3
Cas9-sgRNA (Cas9-Tet3) were transfected with
poly(I:C), and the relative mRNA expression of Ifnb1
was analyzed.
(D) Relative mRNA expression of Ifnb1 in primary
MEFs overexpressing GFP or TET3 after trans-
fection with poly(I:C).
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.Tet3-het mice generated percentages of splenic macrophages,
peritoneal macrophages (PEMs), or BMDMs similar to WT
mice, as indicated by CD11b+F4/80+ staining (Figure S2A). The
populations of CD4+ T cells, CD8+ T cells and B220+ B cells
were also normal in the spleens of Tet3-het mice (Figure S2B).
In response to poly(I:C) stimulation, IFN-b transcripts were
indeed elevated in Tet3-het macrophages compared with WT
BMDMs, which was observed as early as 1 hr after treatment
(Figure 1E, left). ELISAs showed that IFN-b concentrations
were also increased in the supernatants of poly(I:C)-treated
Tet3-het macrophages (Figure 1F). In addition, knockdown
(KD) of Tet3 in PEMs using specific small interfering RNA (siRNA)
enhanced IFN-b production upon poly(I:C) stimulation (Fig-
ure 1G; Tet3 KD efficiency is shown in the right panel). In
contrast, minor differences in IFN-b production were observed
between lipopolysaccharide (LPS)-stimulated Tet3-het and
WT macrophages (i.e., TLR4 pathway) (Figure 1H). Together,
these data suggest that reduced TET3 expression enhances
IFN-b production in macrophages upon activation of the TLR3
pathway.
TET3 Inhibits IFN-b Production via the RIG-I/MDA-5
Pathway
In addition to TLR3/TLR4, retinoic acid-inducible gene I andmel-
anoma differentiation-associated gene 5 (RIG-I/MDA-5), recep-
tors localized in the cytosol, can also induce type I IFNs against
infection in macrophages (Trinchieri, 2010). We next examined
whether TET3 regulated IFN-b production via the RIG-I/MDA5
pathway. As reported previously, transfection of poly(I:C) using
Lipofectamine can activate the RIG-I/MDA5 pathway (Li et al.,
2015b). We found that the poly(I:C)-transfected Tet3-het
macrophages had substantially enhanced IFN-b mRNA levels
compared to WT cells (Figure 2A). KD of Tet3 in PEMs also
increased IFN-b induction upon poly(I:C) transfection (Figure 2B).
Next, we used Cas9 single guide RNAs (sgRNAs) to target the1098 Cell Reports 16, 1096–1105, July 26, 2016Tet3 gene in mouse embryonic fibroblasts
(MEFs) and confirmed the frameshift
mutations in both alleles of Tet3 after se-
quencing the Cas9-sgRNA-treated MEF
cell clone (Figure S3). The poly(I:C)-trans-fected Cas9-Tet3 MEFs also enhanced IFN-b production via
the RIG-I/MDA5 pathway (Figure 2C). Consistent with these
findings, primary MEFs stably overexpressing TET3 revealed a
significant suppression of IFN-b transcription after poly(I:C)
transfection (Figure 2D). We therefore suggest that TET3 nega-
tively regulates IFN-b production via the TLR3 and RIG-I/MDA5
pathways.
The Enzymatic Activity of TET3 Is Dispensable for the
Suppression of IFN-b Transcription
Considering that TET3 is well known for its conversion of 5-meth-
ylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) (He et al.,
2011; Ito et al., 2010), which is the initial step of active DNA de-
methylation and generally results in gene activation, we were
surprised to observe that TET3 decreased IFN-b production. Ac-
cording to a previous report, TET enhances the expression levels
of the miR-200 family, which then results in repression of miR-
200-family-targeted genes (Hu et al., 2014). Because miRNA-
146a (miR-146a) was suggested as a negative regulator of
RIG-I-dependent type I IFN production and antiviral responses
(Hou et al., 2009; Wu et al., 2013), we assessed whether TET3
enhanced miR-146a expression. However, no difference in
miR-146a expression was observed in WT and Tet3-het macro-
phages (Figure 3A). We next questioned whether the enzymatic
activity of TET3, a methylcytosine dioxygenase, was critical for
IFN-b production. TET3 contains a catalytic domain in its C ter-
minus and a CXXC domain in its N terminus (Figure 3B, left)
(Tan and Shi, 2012). A recent study generated the dioxyge-
nase-dead TET3 mutation (H950Y and D952A, named demethy-
lation mutant) caused by two point mutations in the conserved
Fe2+-binding motif (Gu et al., 2011). In addition, we truncated
the N terminus of TET3 to generate the catalytic domain (CD)
or the catalytic domain containing the H950Y and D952A muta-
tions (Mut-CD). Alternatively, we truncated the catalytic domain
in the C terminus of TET3 to generate its N-terminal region
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Figure 3. The Enzymatic Activity of TET3 Is
Dispensable for the Suppression of IFN-b
Transcription
(A) Relative expression ofmiR-146a in WT and Tet3-
het BMDMs.
(B) Diagram of WT or the mutated or truncated TET3
(left). Relative IFN-b luciferase activity in HEK293T
cells transfected with the indicated forms of TET3,
along with the constitutively active form of IRF3
(right).
(C) Relative mRNA expression of Ifnb1 in WT MEFs,
Cas9-Tet3MEFs, or Cas9-Tet3MEFs reconstituted
with the indicated forms of TET3 and transfected
with poly(I:C).
(D) Relative mRNA levels of Ticam1 (encodes TRIF),
Traf3, Tbk1, and Irf3 in WT and Tet3-het BMDMs left
unstimulated or stimulated with poly(I:C).
(E) Relative IFN-b luciferase activity in HEK293T
cells transfected with vector or TET3 together with
TRIF, TBK1, or the constitutively active form of IRF3
to activate IFN-b production.
(F) Immunoblotting analysis of p-TBK1 in WT and
Tet3-het BMDMs left unstimulated or stimulated
with poly(I:C).
(G) Immunoblotting analysis of p-IRF3 in WT and
Tet3-het BMDMs left unstimulated or stimulated
with poly(I:C).
(H) Immunofluorescence analysis of IRF3 in WT and
Tet3-het BMDMs left unstimulated or stimulated
with poly(I:C) (left). Percentages of cells showing
IRF3+ staining in the nuclei (right). Scale bars
represent 10 mm.
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.(named DCD). WT TET3 or the TET3 mutants were overex-
pressed in HEK293T cells to analyze their suppressive function
using an IFN-b luciferase assay. The demethylation mutant,
CD, and Mut-CD inhibited IFN-b luciferase activity in a manner
similar to that of full-lengthWT TET3 (Figure 3B, right). Moreover,
Mut-CD, as well as CD and WT TET3, could reverse enhanced
IFN-b production in TET3-deficient MEFs to a level comparable
to that found in the WT control MEFs (Figure 3C). In contrast,
the DCD mutation, which has lost the catalytic domain, failed
to inhibit IFN-b induction (Figure 3B, right). This indicates that
the catalytic domain of TET3 is critical for IFN-b suppression
but the enzymatic activity of TET3 is dispensable.
We next asked which key signaling proteins in the TLR3 or
RIG-I/MDA5 pathways were transcriptionally affected by TET3.
TET3 deficiency in macrophages did not affect the mRNA levels
of Ticam1 (which encodes TRIF), Traf3, Tbk1, Irf3, and Rela
(which encodes the nuclear factor kB [NF-kB] p65 subunit)Cellwhen compared to those in WT cells (Fig-
ures 3D and S4A). Using the IFN-b
luciferase reporter, we found that TET3
suppressed TRIF-, TBK1-, and IRF3-
induced IFN-b transcription (Figure 3E).
Phosphorylation levels of TBK1 and IRF3
(Figures 3F and 3G), together with the
degradation of IkB-a and the phosphoryla-tion levels of p65 (Figure S4B), were also not altered in Tet3-het
macrophages after poly(I:C) treatment. Consistent with the unaf-
fected canonical NF-kB pathway, poly(I:C)-treated Tet3-het
macrophages produced levels of IL-6 and TNF-a similar to those
produced by WT cells (Figures S4C and S4D). In addition, the
amount of nuclear-localized IRF3 was not altered in untreated
or poly(I:C)-stimulated Tet3-het macrophages (Figure 3H). These
data suggest that TET3 might function downstream of IRF3,
leading to the key question of whether TET3 directly acts on
the Ifnb1 locus.
The Catalytic Domain of TET3 Binds HDAC1 and SIN3A
We analyzed the mass spectrometry data from TET1 immuno-
precipitation (Cartron et al., 2013; Williams et al., 2011) and
found that the transcriptional corepressor SIN3A and histone de-
acetylase 1 (HDAC1) were potential binding partners of TET1.
Previous studies revealed that HDAC1 forms a transcriptionalReports 16, 1096–1105, July 26, 2016 1099
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(A) Immunoprecipitation using anti-HA antibody in
HEK293T cells transfected with HA-GFP or the HA-
tagged indicated form of TET3, together with GFP-
HDAC1 and FLAG-SIN3A. Immunoblotting analysis
of HA-tagged proteins, GFP-tagged HDAC1, and
FLAG-tagged SIN3A was performed.
(B) Immunoprecipitation using anti-FLAG antibody
in HEK293T cells transfected with FLAG-GFP or the
FLAG-tagged indicated form of TET3, together with
GFP-HDAC1. Immunoblotting analysis of FLAG-
tagged proteins, GFP-tagged HDAC1, and endog-
enous SIN3A was performed.
(C) Immunoprecipitation using anti-FLAG antibody
in primary MEFs transfected with FLAG-GFP or
FLAG-tagged TET3. Immunoblotting analysis of
FLAG-tagged proteins and endogenous HDAC1/
SIN3A was performed.
(D) The relative IFN-b luciferase activity in HEK293T
cells transfected with the indicated plasmids, along
with the constitutively active form of IRF3.
(E) HEK293T cells were transfected with the vector
plasmid or TET3 plasmid, along with TBK1 plasmid.
The cells were treatedwith DMSOor apicidin (1 mM),
and the relative mRNA expression of IFNB1 was
examined.
(F) WT or Cas9-Tet3-targeted MEFs were trans-
fected with poly(I:C), together with treatment with
DMSO or apicidin (1 mM), and the relative mRNA
expression of Ifnb1 was examined.
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.repressor complex on the IFNB1 locus (Nusinzon and Horvath,
2006). We therefore examined whether TET3 interacted with
SIN3A or HDAC1 to regulate IFN-b transcription. FLAG-tagged
TET3 or FLAG-tagged GFP were overexpressed in MEFs that
were left unstimulated or transfected with poly(I:C), and the
MEFs were then stained with anti-FLAG and anti-HDAC1 (Fig-
ure S5). In both unstimulated and poly(I:C)-stimulated MEFs,
TET3 was mainly located in the nuclei and colocalized with
HDAC1 (Figure S5). Next, we found that the hemagglutinin (HA)-
tagged full-length TET3 or its DNA demethylation function-dead
mutant (TET3-Mut) could precipitate GFP-fused HDAC1 and
FLAG-taggedSIN3A (Figure4A,HA immunoprecipitation (IP) sam-
ples: lane 2 versus lane 3). Furthermore, the catalytic domain of
TET3 (TET3-CD), but not its N-terminal domain (TET3-DCD), re-
tained the interaction with HDAC1 or SIN3A (Figure 4A, lane 4
versus lane 5). We confirmed that the TET3Mut-CDmutant could
also immunoprecipitate endogenous SIN3A or the transfected
GFP-tagged HDAC1 (Figure 4B, FLAG IP samples: lanes 21100 Cell Reports 16, 1096–1105, July 26, 2016and 3). Because the current commercial or
self-developed antibodies against TET3
were not able to immunoprecipitate or
detect endogenous TET3, we precipitated
FLAG-tagged TET3 in primary MEFs and
found that TET3 could indeed interact with
endogenousHDAC1andSIN3A (Figure4C).Next, we analyzed whether the TET3-HDAC1-SIN3A complex
inhibited IFN-b production. Overexpression of HDAC1 reduced
IFN-b induction to 48.2%, and co-expression of TET3 further
suppressed this to 21.6% (Figure 4D), suggesting a synergistic
inhibition effect. Importantly, treatment with apicidin, an HDAC1
inhibitor (Huber et al., 2011), significantly enhanced IFN-bexpres-
sion in HEK293T cells and also rescued the reduced IFN-b levels
in TET3-overexpressing cells (Figure 4E). Next, we examined this
phenotype in primary MEFs. Upon poly(I:C) transfection, apicidin
treatment augmented IFN-b production in WT MEFs, which
reached a level comparable to that found in TET3-deficient
MEFs (Figure 4F). These data suggest that TET3 might inhibit
IFN-b transcription through HDAC1.
TET3 Promotes the Interaction of HDAC1 or SIN3A with
the Ifnb1 Promoter
Next, we performed chromatin immunoprecipitation (ChIP) as-
says to address how TET3, HDAC1, and SIN3A cooperated
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Figure 5. TET3 Promotes the Interaction of
HDAC1 or SIN3A with the Ifnb1 Promoter
(A–C) ChIP assays followed by qPCR for FLAG-
tagged (A) TET3, (B) HDAC1, and (C) SIN3A in the
IFNB1 promoter in HEK293T cells transfected with
the indicated plasmids. The constitutively active
form of IRF3 (FLAG-IRF3-5D) served as a positive
control.
(D) ChIP assays followed by qPCR for HDAC1 in the
Ifnb1 promoter in WT or Cas9-Tet3-targeted MEFs
left unstimulated or transfected with poly(I:C).
(E) ChIP assays followed by qPCR for HDAC1 in the
Ifnb1 promoter in WT or Tet3-het PEMs left un-
stimulated or transfected with poly(I:C).
(F) ChIP assays followed by qPCR for IRF3 and RNA
polymerase II in the Ifnb1 promoter in WT or Cas9-
Tet3-targetedMEFs left unstimulated or transfected
with poly(I:C).
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.and interacted with the Ifnb1 promoter. The constitutively active
form of IRF3 (termed IRF3-5D) was used as a positive control
(Figures 5A–5C). To compare the relative amount of TET3,
HDAC1, SIN3A, or IRF3-5D enrichment in the IFNB1 promoter,
these molecules were all tagged with FLAG for ChIP assays us-
ing anti-FLAG antibodies (Figures 5A–5C). TET3 and HDAC1
were able to bind to the IFNB1 promoter (Figures 5A and 5B,
lane 2). Interestingly, coexpression of HDAC1 and SIN3A further
enhanced the binding of TET3 to the IFNB1 promoter (Figure 5A,
lane 3 versus lane 2), and coexpression of TET3 further
enhanced the binding of HDAC1 or SIN3A to the IFNB1 promoter
(Figures 5B and 5C, lane 3 versus lane 2). We then tested this
phenotype using WT or TET3-deficient cells, which were left un-
treated or transfectedwith poly(I:C). The amount of HDAC1 in the
Ifnb1 promoter was decreased in WT MEFs and PEMs upon
poly(I:C) transfection, which was in agreement with the inhibitory
effect of HDAC1 on IFN-b transcription (Figures 5D and 5E, white
bars). Importantly, TET3-deficient MEFs or Tet3-het PEMs
further removed a significant amount of HDAC1 from the Ifnb1
promoter (Figures 5D and 5E, black bars), which was correlated
with elevated binding of IRF3, RNA polymerase II (POLR2A), andCellp65 to the Ifnb1 promoter in TET3-deficient
MEFs (Figures 5F and S4E). This suggests
that TET3 elevates the occupancy of
HDAC1 and SIN3A in the Ifnb1 promoter
for the reduction of histone acetylation,
which might result in impaired binding of
IRF3 and RNA polymerase II for IFN-b
transcription.
TET3 Inhibits Antiviral Responses
To identify the role of TET3 in viral clear-
ance, we first analyzed the expression of
TET3 in PEMs after challenge with vesicu-
lar stomatitis virus (VSV; an RNA virus).
GFP was inserted into the VSV genome,
which enabled us to assess the viral loadby immunofluorescence microscopy or fluorescence-activated
cell sorting (FACS). Consistent with the results in the poly(I:C)-
treated macrophages, the mRNA levels of Tet3 were reduced
in the VSV-infected murine macrophages (Figure 6A). Peripheral
blood mononuclear cells (PBMCs) from mice infected with influ-
enza virus (A/Puerto Rico/8/1934 H1N1 strain) also had
decreased the mRNA levels of Tet3 (Figure S6A). We then in-
fected WT and Tet3-het PEMs with VSV, Sendai virus (SeV; an
RNA virus), or herpes simplex virus (HSV; a DNA virus). After
infection with these viruses, Tet3-het macrophages increased
mRNA levels of Ifnb1 (Figure 6B) as well as Ifna2 (Figure 6C,
left) compared to WT macrophages. In agreement with this,
Tet3-het macrophages increased mRNA levels of interferon-
stimulated genes (ISGs), including Mx1, Oas1a, Ccl5, and
Cxcl10 (Figure 6C). TET3-deficient MEFs also had increased
mRNA levels of Ifnb1 and Ifna2 as well as other antiviral genes
upon VSV challenge (Figure S6B). To examine whether TET3
caused primary macrophages to clear viruses, we analyzed the
viral load of VSV in infected PEMs. The percentage of VSV-
GFP+ was significantly lower in Tet3-het PEMs than in WT
PEMs as determined by fluorescence imaging analysis orReports 16, 1096–1105, July 26, 2016 1101
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B Figure 6. TET3 Inhibits Antiviral Responses
(A) Relative mRNA expression of Tet3 in PEMs that
were uninfected (Mock) or infected with GFP-
fused VSV.
(B) Relative mRNA expression of Ifnb1 in WT and
Tet3-het PEMs infected with vesicular stomatitis
virus (VSV), Sendai virus (SeV), or herpes simplex
virus (HSV).
(C) Relative mRNA expression of the indicated
interferon-stimulated genes in WT and Tet3-het
PEMs after VSV infection.
(D) Representative images of the bright field and
GFP fluorescence from WT or Tet3-het PEMs after
VSV infection for 16 hr. Scale bars represent
100 mm.
(E) FACS analysis of the viral load (indicated by
VSV-GFP positive cells) in WT or Tet3-het PEMs
after VSV infection for 16 hr (left). Statistics showing
the percentages of VSV-GFP-positive WT or Tet3-
het PEMs (right).
(F) Relative mRNA expression of IFNB1 in VSV-in-
fected control or TET3-overexpressing HEK293T
cells.
(G) Relative levels of VSV genomic RNA in VSV-in-
fected control or TET3-overexpressing HEK293T
cells.
Error bars represent the mean ± SD of at least three
independent experiments; *p < 0.05, **p < 0.01,
***p < 0.001; NS, not significant.FACS analysis (Figures 6D and 6E), suggesting better viral clear-
ance in Tet3-het macrophages. Consistently, TET3 overexpres-
sion in HEK293T cells decreased themRNA levels of IFNB1 upon
VSV infection (Figure 6F). Furthermore, we observed a higher
amount of VSV genomic RNAby qRT-PCR in TET3-overexpress-
ing HEK293T cells (Figure 6G). Taken together, we propose that
lower TET3 expression elevates type I IFN production and pro-
tects the host against viral infection.
DISCUSSION
Multiple studies have suggested that CpG methylation in gene
promoters leads to gene suppression in mammalian cells.
Because TET3mediates DNA demethylation (Hu et al., 2015; Ta-
hiliani et al., 2009), wewere surprised to find that TET3 negatively1102 Cell Reports 16, 1096–1105, July 26, 2016regulates IFN-b production. Previous work
has revealed that TET3 can promote
microRNA expression, which then ac-
counts for the suppression of target genes
(Hu et al., 2014). Although miR-146a is a
well-known suppressor in the type I IFN
pathway, we found comparable levels of
miR-146a in both WT and Tet3-het macro-
phages. We could not exclude the involve-
ment of other microRNAs, but expression
levels of the key signal proteins that are
known to regulate type I IFN production
were similar in WT and TET3-deficient
macrophages. This suggests that TET3
might directly regulate IFN-b productionat the transcriptional level. Although the IFNB promoter is a
non-CpG promoter (Shestakova et al., 2001), we found that
TET3was able to directly regulate IFN-b transcription. Moreover,
the oxygenase-dead mutant of TET3 was capable of suppress-
ing IFN-b transcription to levels similar to those found in WT
TET3. This further suggests that TET3 might function in a DNA-
demethylation-independent manner. Indeed, TET3 interacted
and cooperated with HDAC1, a well-known histone deacetylase
and gene repressor, which led to the suppression of IFN-b tran-
scription. These findings indicate that TET3 not only regulates
gene expression via DNA demethylation but also targets non-
CpG promoters by recruiting other binding partners. Our study
elucidates the role of TET3 as a scaffolding protein, which by-
passes its classical DNA demethylation function and targets
non-CpG promoters.
Our findings and those of others together suggest that
TET1, TET2, or TET3 could bind to HDAC1 or HDAC2 (Cartron
et al., 2013; Williams et al., 2011; Zhang et al., 2015). In addi-
tion, the occupancy of HDAC1 in the Ifnb1 locus was further
elevated in the presence of TET3, which was in agreement
with the recognized role of HDAC1 in inhibiting IFN-b produc-
tion (Nusinzon and Horvath, 2006). A recent study has sug-
gested that TET2 interacts with HDAC2 to suppress IL-6
production, which is also independent of DNA demethylation
(Zhang et al., 2015). Our study and this finding together suggest
that TET3 and TET2 are able to serve as a repressor rather than
an activator during gene transcription, which is dependent on
HDAC1 or HDAC2, but not on DNA demethylation. It would
be interesting to further examine whether this represents a
common scenario in the TET family (e.g., whether the TET1-
HDAC1 or TET1-HDAC2 complex might also regulate gene
expression independent of DNA demethylation). The discovery
of the TET-HDAC repressor complex extends our understand-
ing of the coordination of histone deacetylation and methylation
for gene expression.
Compared to Tet1 and Tet2, we found that mRNA expression
levels of Tet3 are relatively higher in macrophages. However, the
function of TET3 in the immune system was unknown. In this
study, we demonstrated that TET3 inhibits the production of
type I IFNs in macrophages and dampens the ability to clear viral
infections. Upon poly(I:C) stimulation or viral infection, TET3
expression is decreased in macrophages and PBMCs. Consid-
ering the negative role of TET3 in type I IFN production, the lower
expression of Tet3 in virally infected macrophages confers an
advantage to the host for defending against pathogens.
Currently, with US Food and Drug Approval approval of two
HDAC inhibitors (HDACis), vorinostat and romidepsin (West
and Johnstone, 2014), HDACis are best characterized as anti-
cancer agents because of their ability to reactivate gene expres-
sion and inhibit the growth and survival of tumor cells
(Johnstone, 2002). Considering that the biological outcome of
HDACis depends on the specificity of the HDACis as well as
the intrinsic operation of cell-signaling pathways, it would be
important to further examine whether the TET3-HDAC1 axis
could be a therapeutic target for treating type I IFN-related infec-
tious diseases as well as autoimmune diseases.
EXPERIMENTAL PROCEDURES
Mice
Tet3-hetrozygous mice were on the 129/B6 background, as described previ-
ously (Gu et al., 2011). 8- to 16-week-old littermates were used in this study.
All mice were bred under specific pathogen-free conditions at the Animal
Care Facility of Shanghai Institute of Biochemistry and Cell Biology (SIBCB),
CAS. Animal studies were approved by the institutional animal facility of
the Shanghai Institutes for Biological Sciences (protocol IBCB0057) and the
National Institute for Viral Disease Control and Prevention.
Macrophage Preparation
BMDMs were derived from bone marrow cells cultured in L929 conditioned
medium, and PEMs were harvested from mice injected intraperitoneally (i.p.)
with 3.0 ml 3% Brewer thioglycollate medium, as previously described (Zhang
et al., 2014). The macrophages were cultured in complete DMEM supple-
mented with 10% (vol/vol) fetal bovine serum (FBS), penicillin, and strepto-
mycin (100 U/ml).Antibodies and Reagents
Anti-p-IRF3 (Ser396) and anti-p-TBK1 (Ser172) were from Cell Signaling Tech-
nology. Anti-IRF3, anti-Sin3a, anti-b-actin, and anti-GAPDH were from
Abcam. Anti-HDAC1 was from Millipore. LPS, anti-FLAG, and anti-HA were
from Sigma. Protein G Sepharose was from GE Healthcare. The ELISA kit
for IFN-b was from PBL. Poly(I:C) HMW was from InvivoGen. Apicidin was
from Cayman Chemical.
Stable Cell Lines
FLAG-tagged murine TET3 (WT, CD, and Mut-CD) was sub-cloned into the
retroviral vector pMIGR-IRES-GFP and co-transfected with pCL-10A into
HEK293T cells. Retroviral supernatants were collected and used to infect
MEFs to generate stable cell lines.
Generation of TET3-Deficient MEFs by Cas9-sgRNA
TET3-deficient MEFs were generated by CRISPR (clustered regularly inter-
spaced short palindromic repeats)-associated protein-9 nuclease (Cas9)-
mediated genome engineering as previously described (Zhong et al., 2015).
In brief, the pX330-Tet3-sgRNA-mCherry plasmid was kindly provided by
Dr. J. Li (SIBCB, CAS). MEFs were transfected with the pX330-Tet3-sgRNA-
mCherry plasmid using Lipofectamine 2000 (Life Technologies) according to
the manufacturer’s instructions. 48 hr after transfection, mCherry-positive
MEFs were sorted with flow cytometry (FACS Aria II, BD Biosciences) and
seeded as single cells into 96-well plates. Genomic DNA was extracted from
single clones expanded from single cells and was analyzed by Sanger
sequencing. One clone with both alleles mutated (Figure S3) was chosen as
the representative of the Cas9-Tet3-targeted MEFs.
siRNAs and qRT-PCR
SMART pool siRNA probes (Dharmacon) were transfected into PEMs with
Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s instruc-
tions. Total RNA was extracted from cells with RNAiso Plus (Takara). cDNA
was generated with M-MLV transcriptase (Takara) and random hexamers
(Sangon). qRT-PCRwas performed on a CFX-96 real-time PCR detection sys-
tem (Bio-Rad) with SYBR Green Master Mix (DBI Bioscience).
ChIP Assay
ChIP assays were performed with the EZChIP kit (Millipore) according to the
manufacturer’s instructions. In brief, cells were fixed with 0.9% formaldehyde
and quenched with glycine. Then, the cells were ultrasonicated with a Bio-
ruptor (Diagenode). The supernatants were collected and diluted, and the
indicated antibodies were added for overnight incubation. DNA-protein
complexes were immunoprecipitated by protein G Sepharose, followed by
washing, eluting, and reverse crosslinking processes. The DNA was then pu-
rified and quantified by qRT-PCR.
Dual-Luciferase Reporter Assay
The pGL3-IFN-b luciferase reporter plasmid was kindly provided by
Dr. C. Wang (SIBCB, CAS). HEK293T cells were transfected with the IFN-b
luciferase reporter, TK-renilla, and the indicated plasmids. The activities of
the reporters were measured using a dual-luciferase reporter assay system
(Promega) according to the manufacturer’s instructions.
Poly(I:C) Treatment and Viral Infections of Macrophages
Poly(I:C) treatment was described previously (Zhang et al., 2014). In brief, to
activate the TLR3 pathway, poly(I:C) was added to the medium to a final con-
centration of 10 mg/ml. To activate the RIG-I/MDA-5 pathways, poly(I:C)
(10 mg/ml) was transfected into cells with Lipofectamine 2000 (Invitrogen). Viral
infections in macrophages have been described previously (Du et al., 2015). In
brief, unless indicated, virus was added to serum-free medium and infected
cells for 1.5 hr. The cells were incubated with virus-free serum-containing me-
dium for another 1.5 hr and then harvested.
Immunoprecipitation
Immunoprecipitation was described previously (Li et al., 2015a). In brief,
HEK293T cells or MEFs overexpressing the indicated proteins were washed
twice with ice-cold PBS before being harvested in ice-cold lysis bufferCell Reports 16, 1096–1105, July 26, 2016 1103
(100 mM KCl, 1% Triton X-100, 2 mM EDTA, and protease and phosphatase
inhibitors, pH 7.5). Whole-cell lysates were incubated with the indicated anti-
bodies, followed by protein G Sepharose incubation at 4C. The Sepharose
beads were then washed three times with lysis buffer and resuspended in
an appropriate amount of SDS-PAGE loading buffer. The samples were
analyzed by immunoblotting analysis.
Statistical Analysis
Statistical significance was determined by a two-tailed Student’s t test or a
two-way ANOVA with GraphPad Prism 6. A p value of less than 0.05 was
considered statistically significant.
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